Why is Mangalam Drugs falling/rising?

As of 30-Jul, Mangalam Drugs and Organics Ltd is experiencing a price increase, currently at Rs 89.20, reflecting a rise of Rs 2.0 or 2.29%. Today's price summary indicates that the stock has outperformed its sector by 1.95% and has gained after four consecutive days of decline. It opened with a significant gain of 3.61% and reached an intraday high of Rs 90.4. Despite this positive movement, the stock has shown a negative return of -19.64% over the past year and has underperformed against the benchmark over the last three years. The company has a very attractive valuation with a high return on capital employed (ROCE) of 8.6, and while profits have risen by 176.5%, the stock is trading at a discount compared to its peers. However, it faces challenges such as a high debt to EBITDA ratio and a significant drop in quarterly profits and net sales.
In the broader market context, the stock's short-term performance contrasts with the benchmark, as it has gained 10.30% over the past month while the Sensex has declined by 2.54%. This indicates that Mangalam Drugs is currently showing resilience in a challenging market environment. However, the stock's year-to-date performance remains concerning, with a decline of 23.07% compared to the Sensex's increase of 4.28%. The falling investor participation, as evidenced by a 43.3% drop in delivery volume, suggests caution among investors despite today's positive movement. Overall, while the stock is rising today, its long-term fundamentals and historical performance raise questions about its sustainability.